In progressed type 2 diabetes, i.e. when the effect of the vital, blood sugar-regulating hormone insulin is reduced (insulin resistance) in conjunction with a substantial reduction in the body’s own insulin secretion, treatment is performed with insulin preparations to be administered into the subcutaneous fatty tissue alone or in combination with other antidiabetics [7]. This evidence concerns the gene INS and type 2 diabetes mellitus.